Global Vaccine Safety

Intranasal influenza virus vaccine

Extract from report of GACVS meeting of 3-4 December 2003, published in the WHO Weekly Epidemiological Record on 16 January 2004

The Committee considered safety issues pertaining to a new generation influenza vaccine, administered by the intranasal route. It is a live vaccine, and there are concerns about viral shedding and thus of the potential risk of person-to-person transmission. In the United States, the press has reported that more than 5 million doses have been manufactured, but probably no more than 400 000 had been distributed by the end of November 2003. Comprehensive surveillance has been put in place for monitoring safety. GACVS will review in detail the post-licensure safety data of the vaccine at its June 2004 meeting.